Back to search

Article

The local therapy strategy in progressive ALK or EGFR non-small cell lung cancer

2026-07-16

Abstract excerpt

<title>Abstract</title> <p> Background Tyrosine kinase inhibitors ( <italic>TKIs</italic> ) are the standard treatment for metastatic non-small cell lung cancer ( <italic>NSCLC</italic> ) harboring actionable genetic alterations. Despite high response rates, resistance to TKIs inevitably develops. Local therapy ( <italic>LT</italic> ) to progressing lesions while continuing TKI aims to prolong TKI benefit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8424c4f3-33ab-5b75-9013-49e2130e6474
DOI
10.21203/rs.3.rs-10051586/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The local therapy strategy in progressive ALK or EGFR non-small cell lung cancerDOI 10.21203/rs.3.rs-10051586/v1
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity
Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.Semantic proximity
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease and Oligo-Progressive Disease in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.Semantic proximity
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.Semantic proximity
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Semantic proximity
Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.Semantic proximity
Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort.Semantic proximity
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.Semantic proximity
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Semantic proximity
Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment.Semantic proximity
Select a neighboring publication to make it the new centre.